chemotherapy. Methods: This study used the MarketScan and PharMetrics claims databases (January 1, 2002–June 30, 2014) to identify postmenopausal women with HR+/HER2− mBC who failed a nonsteroidal aromatase inhibitor and later initiated a new line of therapy
Search Results
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes
with low toxicity in patients with low-grade tumors. 111 Tamoxifen with alternating megestrol may be used. 112 Aromatase inhibitors have also been used. 113 - 116 Adjuvant Therapy: Thorough surgical staging provides important information to assist
Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes
LCOH-9 and OV-B, 6 of 7; pages 1143 and 1147, respectively). 200 , 212 – 215 Cytotoxic recurrence therapy includes docetaxel, paclitaxel, paclitaxel/ifosfamide, paclitaxel/carboplatin, and VAC. Hormone recurrence therapy includes aromatase inhibitors
Wui-Jin Koh, Nadeem R. Abu-Rustum, Sarah Bean, Kristin Bradley, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Shari Damast, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Emily Wyse, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
–6 months). 40 , 157 Progesterone-based therapy has been shown to provide some benefit with low toxicity in patients with low-grade tumors. 158 Tamoxifen with alternating megestrol 159 and aromatase inhibitors has also been used. 160 – 163 For suspected
Robert W. Carlson, Susan J. Moench, M. Elizabeth H. Hammond, Edith A. Perez, Harold J. Burstein, D. Craig Allred, Charles L. Vogel, Lori J. Goldstein, George Somlo, William J. Gradishar, Clifford A. Hudis, Mohammad Jahanzeb, Azadeh Stark, Antonio C. Wolff, Michael F. Press, Eric P. Winer, Soonmyung Paik, Britt-Marie Ljung, and for the NCCN HER2 Testing in Breast Cancer Task Force
amplification and response to either tamoxifen or aromatase inhibitors. 85 , 88 – 91 Despite inconsistent data, however, HER2 status has been, and may continue to be, considered in clinical decision-making involving hormonal therapies. 92 Trastuzumab with
Philip J. Saylor and Matthew R. Smith
in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer . J Clin Oncol 2008 ; 26 : 4875 – 4882 . 75. Lewiecki EM Miller PD McClung MR . Two-year treatment with denosumab (AMG 162
Jessica K. DeMartino
,N0,M0, or stage II or III hormone receptor-negative breast cancer. NQF #0220: Tamoxifen or third-generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c,N0,M0, or stage II or III
Rashmi Chugh
treated with an aromatase inhibitor yielded a median time to progression of 6 months. 89 Studies of new therapies that block the estrogen signaling pathway show this is a reasonable strategy for treating patients with chondrosarcoma. In vitro studies
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead
women) or an aromatase inhibitor (for postmenopausal women, especially those under 60 years of age or those with concerns of embolism), may be considered as a strategy to reduce the risk of ipsilateral breast cancer recurrence in women with ER
Mary B. Daly, Tuya Pal, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L. Hutton, CGC, Beth Y. Karlan, Seema Khan, Catherine Klein, Wendy Kohlmann, CGC, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, LCGC, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Holly J. Pederson, Gwen Reiser, CGC, Leigha Senter-Jamieson, CGC, Kristen Mahoney Shannon, Rebecca Shatsky, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Matthew B. Yurgelun, Susan D. Darlow, and Mary A. Dwyer
likelihood of benefit with these chemopreventive approaches in individual patients. The aromatase inhibitors (AIs) exemestane and anastrozole have been demonstrated to be effective in preventing breast cancer in postmenopausal women considered to be high
